



Lipid oligonucleotide conjugates as responsive nanomaterials for drug delivery

Oleksandr Pokholenko, Arnaud Gissot, Brune Vialet, Katell Bathany, Alain Thiery, Philippe Barthélémy

► To cite this version:

Oleksandr Pokholenko, Arnaud Gissot, Brune Vialet, Katell Bathany, Alain Thiery, et al.. Lipid oligonucleotide conjugates as responsive nanomaterials for drug delivery. *Journal of materials chemistry B*, 2013, 1 (39), pp.5329-5334. 10.1039/C3TB20357C . hal-02484550

HAL Id: hal-02484550

<https://hal.science/hal-02484550>

Submitted on 19 Feb 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Lipid Oligonucleotide Conjugates as Responsive Nanomaterials for Drug Delivery

Oleksandr Pokholenko,^{a,b,e} Arnaud Gissot,^{a,b,e} Brune Vialet,^{a,b} Katell Bathany,^c Alain Thierry,^d and Philippe Barthélémy^{*a,b}⁵ Received (in XXX, XXX) Xth XXXXXXXXXX 20XX, Accepted Xth XXXXXXXXXX 20XX

DOI: 10.1039/b000000x

We report Lipid Oligonucleotide conjugates (LONs) bearing either two or three hydrophobic chains. LONs self-assemble into micellar aggregates, which provide a suitable reservoir for hydrophobic drug such as paclitaxel. Our results demonstrate that the composition of the LONs both in terms of the lipid and the oligonucleotide sequence impact their ability to host lipophilic molecules. Interestingly, binding of the complementary oligonucleotide selectively induces the release of part of the drug payload of the aggregates. These LON based micelles, which efficiently host hydrophobic drugs represent an original stimuli-responsive drug delivery system.

1 INTRODUCTION

The ability of DNA to form predictable and complex nano-architectures is virtually unlimited.¹ Recently, much attention has been given to Lipid-Oligonucleotide bioconjugates (LONs).^{2,3} These amphiphiles feature an oligonucleotide sequence as the polar head and at least one lipid moiety inserted either at the 3'- or 5'-end of the oligonucleotide or within the sequence. Interestingly, LONs self assemble to give aggregates such as micelles⁴⁻⁶ and vesicles.^{7,8} Shape-shifting "smart" LONs have also been described.⁹⁻¹¹

The appended lipidic segment of LONs brings about new properties to these surfactants like enhanced antisense activities,¹² tagging of vesicles¹³⁻¹⁷ or lipid bilayers,^{4,18-21} and biological membranes.²²⁻²⁴ LONs have also been successfully implemented in original detection schemes for nucleic acids,^{25,26} and as biotechnological tools.^{27,28} Besides, LON aggregates feature a lipophilic core or reservoir, which can be used for the loading of hydrophobic drugs. We hypothesized that the drug loading of the aggregates could be modulated via the hybridization of the complementary ON sequence, thus making these LON aggregates an attractive original nanomedicine.²⁹ Ideally, biologically relevant complementary ON target sequences, as for instance




Figure 1. A) Double and triple chain LONs synthesized in this study. B) Schematic representation of single and double strand LON based micelles loaded with an antitumoral drug: Paclitaxel.

miRNA, could be used to specifically trigger the release of the drug in vivo.

In the present study, LONs were investigated for their ability to self assemble and load paclitaxel (Figure 1). In order to optimize the inclusion of the lipophilic paclitaxel, LONs were synthesized with either 2 or 3 hydrocarbon chains attached at their respective 5' end (Figure 1A). We show that LON based micelles, which are efficient host for hydrophobic drugs like paclitaxel, can provide stimuli-responsive drug-carriers sensitive to the presence of a complementary oligonucleotide.

2 MATERIALS AND METHODS

2-1 Synthesis of the triple chain phosphoramidite 4

Details for the experimental procedure for the synthesis of the phosphoramidite 4 can be found in the supporting information. Of note, MALDI-MS of the very lipophilic 2,2,2-tris-stearyl acetic acid 3 required the use of a DCTB matrix (trans-2-[3-(4-tert-butylphenyl)-2-methyl-2-propenylidene]malononitrile) doped with Ag⁺ (or Na⁺).

Procedure: this analysis was performed by the CESAMO (Bordeaux, France) on a Voyager mass spectrometer (Applied

^a Université Bordeaux Segalen, 146 rue Léo Saignat 33076 Bordeaux Cedex, France. Fax: 33 5 5757 1015; Tel: 33 5 5757 4853; E-mail: philippe.barthelemy@inserm.fr;

^b INSERM U869, Bordeaux, F-33076, France.

^c Université Bordeaux, CBMN - UMR 5248, Pessac F-33600, France.

^d Université Marseille, IMBE - CNRS UMR 7263, Marseille France.

^e These authors contributed equally to the work

† Electronic Supplementary Information (ESI) available: Experimental procedures, NMR, MS, TEM, SEM images and DLS data. See <http://dx.doi.org/10.1039/b000000x/>

Biosystems). The instrument is equipped with a pulsed N₂ laser (337 nm) and a time-delayed extracted ion source. Spectra were recorded in the positive-ion mode using the reflectron and with an accelerating voltage of 20 kV. Samples were dissolved in CH₂Cl₂ at 10 mg/ml. The DCTB matrix solution was prepared by dissolving 10 mg in 1 ml of CH₂Cl₂. A solution of cationisation agent (AgTFA, 10 mg/ml) was also prepared. The solutions were combined in a 10:1:1 volume ratio of matrix to sample to cationisation agent. One to two microliters of the obtained solution was deposited onto the sample target and vacuum-dried.

2-2 LON synthesis and MS

LONs were synthesized using the phosphoramidite methodology on an automated Expedite 8909 DNA synthesizer at the μ mole scale on 500Å primer support (loading: 60-100 μ mol/g, Link technologies, Synbase Control Pore Glass). Autoclaved milliQ water has been used whenever water was required for the handling of oligonucleotides or LONs.

Mass spectra measurements were performed on a MALDI-ToF-ToF mass spectrometer (Ultraflex, Bruker Daltonics, Bremen, Germany). Best results were obtained in the linear mode with positive-ion detection. Mass spectra were acquired with an ion source voltage 1 of 25 kV, an ion source voltage 2 of 23.5 kV, a lens voltage of 6 kV, by accumulating the ion signals from 1000 laser shots at constant laser fluence with a 100Hz laser. External mass calibration was achieved using a mixture of oligonucleotides dT₁₂-dT₁₈ (Sigma).

1:1 mixture of samples of LONs (~20-50 μ M) and matrix was spotted on a MALDI target and air-dried before analysis.

The performance of the following matrices was evaluated: 2,5-dihydroxybenzoic acid (DHB), 2,4,6-trihydroxy-acetophenone (THAP), 3-hydroxypicolinic acid (3-HPA) and 2,6-dihydroxyacetophenone (DHA). THAP at a concentration of 20 mg/mL in a 4:1 mixture of ethanol and 100mM aqueous ammonium citrate was shown to yield optimal mass spectral results.

2-3 Transmission and Scanning Electron Microscopy (TEM and SEM)

Transmission Electron Microscopy (TEM). Samples were imaged by negative staining microscopy with a Hitachi H 7650 electron microscope. Samples containing LONs (concentrations and mean sizes are indicated in TEM images) were transferred to a carbon-coated copper grid for ten minutes. The sample was then dried and stained with 2.5 % (W/W) of uranyl acetate in water for five minutes.

Scanning Electron Microscopy (SEM). Samples were examined at an accelerating voltage of 10 kV. Typically 20 ml of sample containing the LON aggregates were dried spread on polished stainless steel platelets and then coated with a 6-10 nm layer of gold-palladium alloy under vacuum with a sputter Coater Balzers SCD050. Observations were made with a Philips XL30S FEG instrument.

2-4 Solubilization of paclitaxel in aqueous solutions of LONs

Representative example: paclitaxel solubilization by a mixture of dA₁₅ and 2LON T₁₅ oligonucleotides.

Preparation of the samples. For the experiments of LON-assisted dissolution of paclitaxel, 40 nmol of dA₁₅ and ²LON-T₁₅ were dried (speedvac). 0.2 mL PBS (10 mM phosphate buffer pH

7 + 100 mM of NaCl) were then added and the mixture vortexed.

The obtained aqueous solution was added to a test tube containing 0.6 mg of thoroughly dried paclitaxel. Vortexing and then sonication at 30°C for 30 min produced turbid colloidal suspensions (pure buffer solutions gave clear solutions above the paclitaxel precipitate). Subsequent centrifugation (2000 rpm; 20min) followed by filtration through a 450nm filter gave the sample ready for HPLC analysis.


For the release of paclitaxel experiments, the procedure was similar to the one described above except that dA₁₅ was not added in the first place. After the ²LON T₁₅ + paclitaxel solution has been filtered, the latter was added to an equimolar amount of dry dA₁₅ or control oligonucleotide. The mixture was vortexed and left standing at room temperature for 8h before the suspension was filtered again. The long period of time left for the hybridization of the 2 oligonucleotides was necessary to leave time for the released paclitaxel molecules to aggregate in large filterable particles.

Determination of paclitaxel concentrations. The concentrations of paclitaxel in the different aqueous solutions were measured by reverse phase (Macherey Nagel EC 250/4 Nucleosil 120-5 C4) HPLC with detection at 227 nm. Elution conditions (eluent A (V/V): 5% CH₃CN / 95% 0.1 M TEAA pH 7; eluent B: 80% CH₃CN / 20% 0.1 M TEAA pH 7): isocratic (16% of B) for 2 mns, 16->90% of B after 28 mns and back to 16% of B. A representative chromatogram is included in the supplementary information.

The paclitaxel concentrations were estimated by measuring the area of the paclitaxel peak in the chromatogram after injection of a fixed volume (45 μ L) of the solution. The latter was translated into a paclitaxel concentration using a calibration curve (see SI). The concentrations tested for the calibration curve spanned the range of paclitaxel concentrations obtained in our paclitaxel-loading experiments.

3 RESULTS AND DISCUSSION

3-1 Chemistry of LONs. LONs were efficiently synthesized using the classical phosphoramidite chemistry for oligonucleotides (see supporting information). While ²LON-A₁₅ and ²LON-T₁₅ were synthesized *via* the phosphoramidite derived from the palmitone ketal of uridine as described before,¹⁴ the synthesis of the second triple hydrocarbon chain modifier is illustrated in Scheme 1 starting from diethyl malonate and stearyl bromide. Malonic ester synthesis first afforded the bis-stearyl



Scheme 1 Synthesis of the triple chain phosphoramidite synthon
Reagents and conditions: a) NaH, stearyl bromide, dry DMF, 0-50°C, 16h b) KOH, iPrOH/H₂O, 80°C, 16h c) aq. H₂SO₄, 77%, 2 steps d) LDA, stearyl bromide, dry THF, RT-50°C, 68% e) LAH, dry THF, 60°C f) N(iPr)₃P(OCNE)Cl, dry CH₂Cl₂, RT




Figure 2. Examples of TEM (A, and magnification B) and SEM (C) images observed with $^2\text{LON-A}_{15}$ ($C=40 \mu\text{M}$ in water). Drawings showing i) the dimensions of $^2\text{LON-A}_{15}$ estimated in the maximum elongated conformation (D). The molecule of $^2\text{LON-A}_{15}$ was constructed using MarvinSketch software and optimized in Dreiding force field, see SI for details.

adduct **1**, which was further hydrolyzed and decarboxylated to the monoacid **2**. The latter was then alkylated with stearyl bromide after deprotonation with an excess of LDA to give the triple chain monoacid **3**. Of note and probably because of its high lipophilicity, **3** proved quite reluctant to traditional mass analysis (ESI and maldi using conventional organic matrices). Mass analysis (maldi) of this compound required the use of a DCTB matrix (trans-2-[3-(4-tert-butylphenyl)-2-methyl-2-propenylidene]malononitrile) doped with Ag^+ or Na^+ (SI). Reduction with LAH followed by phosphitylation of the resulting alcohol afforded the target phosphoramidite **4** ready for the automated, solid supported synthesis of oligonucleotides. Oligonucleotides dT₁₅ and dA₁₅ were derivatized with these 2 phosphoramidites (Figure 1A). The coupling efficiency of the new phosphoramidite **4** to the elongating oligonucleotide sequence could not be directly determined due to the absence of the DMT protecting group in this phosphoramidite. Nevertheless, the coupling yield was good as estimated by the integration of the mass spectrum signals from the crude reaction mixture of $^3\text{LON-T}_{15}$ (see SI) and the excellent 40% final yield of the HPLC-purified LON. The oligonucleotide sequences dA₁₅ (adenine 15-mer) and dT₁₅ (thymidine 15-mer) were appended to these 2 lipophilic modifiers to probe the influence of the oligonucleotide sequence. This resulted in the synthesis of four different LONs (Figure 1A).

3-2 Physicochemical properties of LONs. As true surfactants, LONs can self assemble in aqueous media. Both the lipophilic segment and the oligonucleotide sequence were found to markedly influence the aggregation behavior of our LONs. Overall and not surprisingly, adenosine-containing LONs ($^3\text{LON-A}_{15}$ and $^2\text{LON-A}_{15}$) were less soluble in water than their thymidine counterparts ($^2\text{LON-T}_{15}$ and $^3\text{LON-T}_{15}$). If $^2\text{LON-T}_{15}$ aqueous solutions did not show any sign of precipitation after HPLC purification and storage, $^2\text{LON-A}_{15}$ was only sparingly soluble in water (up to ca. 50 μM). Yet, addition of a buffer (PBS or AcOH/TEA) resulted in a better solubilisation of $^2\text{LON-A}_{15}$. Interestingly, the presence of the triple chain motif resulted in a




Figure 3. LON-assisted aqueous solubilization of paclitaxel in 10 mM phosphate buffer and 100 mM NaCl. Oligonucleotide duplexes (when considered) were annealed prior to the addition of paclitaxel.

peculiar behavior of $^3\text{LON-A}_{15}$ and $^3\text{LON-T}_{15}$. The latter could be HPLC-purified and characterized by MS. Yet, a slow aggregation tendency was observed after storage at -20°C , $^3\text{LON-T}_{15}$ being still detectable by MS in the solution (see SI). In contrast, immediate and irreversible aggregation of $^3\text{LON-A}_{15}$ took place after cleavage and deprotection of the crude LON. The aggregates were so stable that MS detection and purification of $^3\text{LON-A}_{15}$ by PAGE or HPLC proved impossible (see SI). Consequently, dynamic light scattering, transmission electron microscopy and SEM experiments were carried out with the solutions of the 3 purified LONs only. Aqueous samples containing LONs were studied under different conditions including pure water and aqueous suspensions of varying ionic strength and temperature (25–45 $^\circ\text{C}$). All the LONs investigated, namely $^2\text{LON-T}_{15}$, $^2\text{LON-A}_{15}$ and $^3\text{LON-T}_{15}$, yielded small spherical objects ranging from approximately 8 to 20 nm in diameter as characterized by DLS, transmission and scanning electronic microscopies (TEM and SEM, see SI). For example, TEM and SEM imaging of $^2\text{LON-A}_{15}$ samples ($C=40 \mu\text{M}$) dissolved in pure water showed micellar aggregates (Figures 2A and 2B). The micellar architecture of these assemblies can be explained based upon the molecular dimensions of 15 nucleobase-long LONs (Figure 2C). Indeed, such molecules are flexible, with cone shape structure and dimensions compatible with the self-aggregation into spherical micelles. The DLS study of $^2\text{LON-T}_{15}$ in water indicates that the size of aggregates is poorly sensitive to ionic strength. Likewise, the size of aggregates is poorly affected by temperature in the 25–45 $^\circ\text{C}$ range or the concentration of the amphiphile (see SI).

3-3 Drug loading experiments. Physicochemical experiments and microscopy observations demonstrated that LONs self-associate into micelle-like aggregates. We hypothesized that the hydrophobic core of LON aggregates could promote the solubilization in aqueous environments of hydrophobic drugs like paclitaxel. To this end, the LONs were solubilized (200 or 300

μM solutions) in 10 mM PBS buffer at pH 7 and 100 mM NaCl. The LON aqueous solutions were bath-sonicated and heated in the presence of a thin film of paclitaxel and the resulting suspensions filtered through a 0.4 μm pore to remove non-incorporated paclitaxel aggregates. The paclitaxel concentrations still remaining in solution were then determined by RP-C₄-HPLC (see SI and figure 3). On one hand and as expected, the more lipophilic ³LON-T₁₅ was superior to ²LON-T₁₅ in the solubilization of paclitaxel (Figure 3, compare I.1 and I.2). Yet, when normalized by the number of methyl and methylene groups present in their structure (30 and 55 for ²LON-T₁₅ and ³LON-T₁₅ respectively), these two LONs exhibit the same ability to solubilize paclitaxel (light grey bars in I.1 and I.2). For a given oligonucleotide sequence, this seems to indicate that the solubility of paclitaxel is proportional to the number of carbon atoms present in the hydrocarbon chains of LONs. On the other hand, the oligonucleotide sequence was quite unexpectedly found to be of prime importance (compare results II.1 and II.4 in Figure 3): ²LON-A₁₅ turned out to be almost twice as potent as ²LON-T₁₅ at solubilizing paclitaxel. The unmodified dA₁₅ and dT₁₅ oligonucleotides being both very poor at solubilizing paclitaxel (results not shown), cooperativity somehow exists between the dA₁₅ and the alkyl segments of ²LON-A₁₅ to host more drug molecules. Besides, when ²LON-A₁₅ and ²LON-T₁₅ complementary single strand DNA (cDNA: dT₁₅ and dA₁₅ respectively) were allowed to hybridize before the paclitaxel solubilizing step, the paclitaxel intake clearly decreases with both ²LON-A₁₅.dT₁₅ and ²LON-T₁₅.dA₁₅ aggregates compared to single-strand (ss) LON (compare results II.1/II.2 and II.4/II.5 respectively). If this decrease remained modest (37%) for ²LON-T₁₅.dA₁₅ aggregates, it reached 61% for ²LON-A₁₅.dT₁₅ micelles. Eventually, the paclitaxel payload of ²LON-A₁₅ and ²LON-T₁₅ aggregates reached the same level (within experimental errors) upon binding the complementary oligonucleotides (compare II.2 and II.5). In other words, the dA₁₅ segment of ²LON-A₁₅ is no longer capable of promoting paclitaxel intake once it is engaged into double-strand (ds) DNA. The importance of the dA₁₅ segment is further illustrated by the paclitaxel loading capability of a 1:1 ²LON-A₁₅:²LON-T₁₅ mixture (Figure 3, II.3). If the global payload of the drug increases in that case, this result is merely the result of the doubling of the effective concentration of alkyl chains. When normalized by the number of methylene groups, one clearly sees that this mixture is indeed less likely to host paclitaxel molecules compared to ²LON-A₁₅ alone (compare grey bars in II.1 and II.3). Interestingly, the drug loading capability of that mixture is within experimental errors equivalent to ²LON-T₁₅ (compare II.3 and II.4). The benefit of having the dA₁₅ sequence in ²LON-A₁₅ is therefore abolished upon annealing of the complementary oligonucleotide.

3-4 Controlled release of paclitaxel. If ds-LONs are clearly less efficient at solubilizing paclitaxel in aqueous buffered solutions compared to ²LON-A₁₅ or ²LON-T₁₅ micellar aggregates, the controlled release of the paclitaxel drug molecules upon annealing of the cDNA has not been evidenced so far. Despite its lower ability to host paclitaxel molecules, these experiments were conducted with ²LON-T₁₅ micellar aggregates for their lesser tendency toward precipitation with time (see the




Figure 4. Selective controlled release of paclitaxel from ²LON-T₁₅ micelles (200 μm based on the LON) upon treatment with the cDNA (10 mM phosphate buffer pH 7, 100 mM NaCl). The measured (by Dynamic Light Scattering in the absence of paclitaxel) mean size of the micellar aggregates is reported on top for each of the oligonucleotide system reported.

physicochemical properties part). Schematically, the filtered micellar suspensions of ²LON-T₁₅ loaded with paclitaxel was subjected either to the cDNA dA₁₅ or the non complementary ss-DNA (5'-GGC TCA CAA CAG GC-3') as a control and the released paclitaxel was again filtered off through 0.4 μm pores (Figure 4). While some paclitaxel molecules were non-specifically released from the ²LON-T₁₅ micelles upon treatment with the ncDNA (ca. 2-fold decrease in paclitaxel loading), the complementary dA₁₅ induced a 5.6-fold decrease thus demonstrating the selective controlled release of the drug.

3-5 Discussions. What drives the release of the drug loaded in the hydrophobic core of the aggregates upon DNA annealing is not obvious at first sight. It must first be noticed that the nature of the LON aggregates is not changed upon binding the cDNA (Figure 4, top) and micellar aggregates are still observed in the presence of the cDNA. Yet, contraction of the micelle was observed following hybridization of the complementary dA₁₅ with ²LON-T₁₅ aggregates (from 14.7 to 11.8 nm). Such contraction of the micellar core was not observed with the ncDNA. These results were quite unexpected. Formation of the rather long and stiff rod-shaped dsDNA was indeed expected to increase the size of the micelle compared to the quite flexible ss-DNA segment of LONs. Interestingly, contraction of the micelle was negligible when ³LON-T₁₅ and dA₁₅ were allowed to hybridize (results not shown). This result suggests that the micellar hydrophobic core of the micelle-associated or not with a change in the aggregation number-experience much of the contraction upon DNA duplex formation and may shed light on the mechanism of the triggered release of paclitaxel from LON micelles. In fact, the ss-DNA polar heads of LONs may experience some conformational freedom in the aqueous phase within the LON aggregates. The surface area occupied by each polar head of ss-LONs may be quite large. Consequently, the LON alkyl chains may be poorly packed within the hydrophobic core thus leaving room for hosting hydrophobic guests. In the

contrary, the stiffness and the rather small cross section of DNA double helices might allow for a better compaction of the alkyl chains within the core of the micelle with the concomitant release of part of the loaded paclitaxel molecules. First attempts to confirm this hypothesis by measuring the surface tension of ²LON-T₁₅ solutions alone and in the presence of the complementary dA₁₅ were quite unsatisfactory because of slow kinetics and complex adsorption isotherms of the LON at the air/water interface.^{30,31} Further investigations are underway to work around this issue.

4 CONCLUSIONS

In this study we present the synthesis of LONs featuring double and triple lipophilic chains. These LONs self-assemble into micelles, which are prone to host paclitaxel molecules within their hydrophobic cores. Our results demonstrate that the composition of the LONs both in terms of the lipid and the oligonucleotide sequence impact their ability to host lipophilic molecules. Interestingly, the drug intake of ²LON-A₁₅ was markedly high compared to other LONs. Overall, the polynucleotide sequence serves three roles: (1) it promotes the transfer of the alkyl chains of the LONs into water, (2) it potentializes the drug intake of the LON aggregates and (3) it can hybridize with the cDNA sequence to trigger the release of the drug. Only two oligonucleotide sequences (dA₁₅ and dT₁₅) have been investigated in this study. Consequently, there is still room for further optimization of the ON length and composition.

Numerous stimuli-bioresponsive drug delivery systems have been developed to induce the release of the drug in response to certain stimuli like pH, temperature, redox potential, enzymes, light, and ultrasound.^{32–34} In this contribution we demonstrate that the drug loading of LON based nanomaterials can be modulated via a complementary (hand-made) oligonucleotide stimulus. LON aggregates afford an original and specific stimuli-bioresponsive alternative to address the drug controlled delivery issue. However, extracellular small nucleic acids such as miRNA could be an appropriate biological target of our system. Indeed, although miRNAs exert their functions inside the cell, these and other classes of RNAs can be found in extracellular body fluids.³⁵ We hope this oligonucleotide-based strategy for the formulation of lipophilic drugs will and other applications in the realm of drug delivery.

ACKNOWLEDGEMENTS

This work has been supported by the French National Agency (ANR) in the frame of its programme blanc (NANAN project no. ANR-08-NANO-028). The authors thank the Bordeaux Imaging Centre (BIC) for technical assistance during TEM observations. O.P. and P.B. acknowledge financial support from the Army Research Office.

Notes and references

- 1 E. Stulz, *Chem. Eur. J.*, 2012, **18**, 4456–4469.
- 2 A. Gissot, M. Camplo, M. W. Grinstaff, and P. Barthélémy, *Org. Biomol. Chem.*, 2008, **6**, 1324–1333.
- 3 A. Patwa, A. Gissot, I. Bestel, and P. Barthélémy, *Chem. Soc. Rev.*, 2011, **40**, 5844–5854.

- 4 C. Gosse, A. Boutorine, I. Aujard, M. Chami, A. Kononov, E. Cogné-Laage, J.-F. Allemand, J. Li, and L. Jullien, *J. Phys. Chem. B*, 2004, **108**, 6485–6497.
- 5 H. Liu, Z. Zhu, H. Kang, Y. Wu, K. Sefan, and W. Tan, *Chem. Eur. J.*, 2010, **16**, 3791–3797.
- 6 M. Anaya, M. Kwak, A. J. Musser, K. Müllen, and A. Herrmann, *Chem. Eur. J.*, 2010, **16**, 12852–12859.
- 7 P. M. Dentinger, B. A. Simmons, E. Cruz, and M. Sprague, *Langmuir*, 2006, **22**, 2935–2937.
- 8 F. Teixeira Jr., P. Rigler, and C. Vebert-Nardin, *Chem. Commun.*, 2007, 1130.
- 9 M. P. Thompson, M.-P. Chien, T.-H. Ku, A. M. Rush, and N. C. Gianneschi, *Nano Lett.*, 2010, **10**, 2690–2693.
- 10 M.-P. Chien, A. M. Rush, M. P. Thompson, and N. C. Gianneschi, *Angew. Chem. Int. Ed.*, 2010, **49**, 5076–5080.
- 11 L. Wang, Y. Feng, Z. Yang, Y.-M. He, Q.-H. Fan, and D. Liu, *Chem. Commun.*, 2012, **48**, 3715–3717.
- 12 G. Godeau, C. Staedel, and P. Barthélémy, *J. Med. Chem.*, 2008, **51**, 4374–4376.
- 13 P. A. Beales and T. K. Vanderlick, *J. Phys. Chem. A*, 2007, **111**, 12372–12380.
- 14 A. Gissot, C. Di Primo, I. Bestel, G. Giannone, H. Chapuis, and P. Barthélémy, *Chem. Commun.*, 2008, 5550–5552.
- 15 T. Maruyama, H. Yamamura, M. Hiraki, Y. Kemori, H. Takata, and M. Goto, *Colloids Surf., B*, 2008, **66**, 119–124.
- 16 P. A. Beales and T. K. Vanderlick, *Biophys. J.*, 2009, **96**, 1554–1565.
- 17 B. Van Lengerich, R. J. Rawle, and S. G. Boxer, *Langmuir*, 2010, **26**, 8666–8672.
- 18 I. Pfeiffer and F. Höök, *J. Am. Chem. Soc.*, 2004, **126**, 10224–10225.
- 19 I. Pfeiffer and F. Höök, *Anal. Chem.*, 2006, **78**, 7493–7498.
- 20 A. Bunge, A. Kurz, A.-K. Windeck, T. Korte, W. Flasche, J. Liebscher, A. Herrmann, and D. Huster, *Langmuir*, 2007, **23**, 4455–4464.
- 21 P. A. Beales and T. K. Vanderlick, *J. Phys. Chem. B*, 2009, **113**, 13678–13686.
- 22 G. G. Borisenko, M. A. Zaitseva, A. N. Chuvilin, and G. E. Pozmogova, *Nucleic Acids Res.*, 2009, **37**, e28.
- 23 M. Loew, R. Springer, S. Scolari, F. Altenbrunn, O. Seitz, J. Liebscher, D. Huster, A. Herrmann, and A. Arbuzova, *J. Am. Chem. Soc.*, 2010, **132**, 16066–16072.
- 24 M. J. Palte and R. T. Raines, *J. Am. Chem. Soc.*, 2012, **134**, 6218–6223.
- 25 A. Gunnarsson, P. Jönsson, V. P. Zhdanov, and F. Höök, *Nucleic Acids Res.*, 2009, **37**, e99.
- 26 A. Gunnarsson, P. Sjövall, and F. Höök, *Nano Lett.*, 2010, **10**, 732–737.
- 27 T. Maruyama, T. Hosogi, and M. Goto, *Chem. Commun.*, 2007, 4450.
- 28 M. Kwak, I. J. Minten, D.-M. Anaya, A. J. Musser, M. Brasch, R. J. M. Nolte, K. Müllen, J. L. M. Cornelissen, and A. Herrmann, *J. Am. Chem. Soc.*, 2010, **132**, 7834–7835.
- 29 P. Couvreur, *Adv. Drug Delivery Rev.*, 2013, **65**, 21–23.
- 30 M. Banchelli, F. Betti, D. Berti, G. Caminati, F. B. Bombelli, T. Brown, L. M. Wilhelmsson, B. Nordén, and P. Baglioni, *J. Phys. Chem. B*, 2008, **112**, 10942–10952.
- 31 M. Banchelli, F. Gambinossi, A. Durand, G. Caminati, T. Brown, D. Berti, and P. Baglioni, *J. Phys. Chem. B*, 2010, **114**, 7348–7358.
- 32 S. Ganta, H. Devalapally, A. Shahiwal, and M. Amiji, *J. Control. Release*, 2008, **126**, 187–204.
- 33 E. Fleige, M. A. Quadir, and R. Haag, *Adv. Drug Delivery Rev.*, 2012, **64**, 866–884.
- 34 X. Huang, X. Jiang, Q. Yang, Y. Chu, G. Zhang, B. Yang, and R. Zhuo, *J. Mater. Chem. B*, 2013, **1**, 1860–1868.
- 35 A. M. Hoy and A. H. Buck, *Biochem. Soc. Trans.*, 2012, **40**, 886–890.